Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Neurology and Neurosurgery
  • Neurology & Neurosurgery News
  • Ravulizumab lacks...

Ravulizumab lacks treatment effect, highlights unmet need for highly effective treatment for ALS

Written By : Medha Baranwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2023-11-18T09:30:44+05:30  |  Updated On 18 Nov 2023 3:09 PM IST
Ravulizumab lacks treatment effect, highlights unmet need for highly effective treatment for ALS
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

USA: A recent study published in JAMA Neurology investigated the safety and efficacy of ravulizumab, a complement C5 inhibitor, in adults with amyotrophic lateral sclerosis (ALS), given the urgent need for additional therapies for ALS.

Findings from the randomized clinical trial (RCT) of 382 adults with ALS showed that ravulizumab failed to slow functional decline and had a similar safety profile as the placebo. The researchers, therefore, emphasize the critical need for highly effective, novel treatments to extend survival and slow function decline in these patients.

Amyotrophic lateral sclerosis is a debilitating, rare, neurodegenerative disease with characteristics of extensive degeneration and death of lower and upper motor neurons, leading to progressive weakness and atrophy of skeletal muscle. Eventually, patients with ALS lose the ability to breathe, eat, speak, and move. Currently, sodium phenylbutyrate, taurursodiol (TURSO), edaravone, and riluzole are the only medications approved by the US FDA that slow ALS progression and there remains a need for more effective therapies.

Previous studies have shown that amplified neuronal C5a-C5a receptor signalling may be associated with disease progression of amyotrophic lateral sclerosis. Ravulizumab, a humanized monoclonal antibody, binds with high affinity to C5. Therefore, Angela Genge, McGill University, Montréal, Québec, Canada, and colleagues aimed to evaluate the efficacy and safety of the terminal complement C5 inhibitor ravulizumab in adults with ALS.

The researchers conducted the parallel-group, multinational, placebo-controlled, double-blind, randomized phase 3 clinical trial from 2020 to 2021 in 81 ALS speciality centres across 17 countries. An unmasked, preplanned nonbinding interim futility analysis was conducted when 33% of participants had completed week 26, wherein a conditional power below 10% would halt the trial.

Of the 478 individuals who were screened, 96 were excluded. Inclusion criteria were a weight of 40 kg or more, a minimal prestudy Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) progression score of –0.3 points per month, and fulfilment of the El Escorial diagnostic criteria.

Study treatment comprised of a placebo or a weight-based dose of IV ravulizumab every 8 weeks until week 42. Participants could continue standard-of-care treatment. A total of 382 participants were randomly assigned in the ratio 2:1 to receive ravulizumab (n = 255; mean age, 58.6 years; 63.1% male) or placebo (n = 127; mean age, 58.0 years; 54.3% male).

The study's primary endpoint was determined as the change from baseline in ALSFRS-R score at week 50 based on the Combined Assessment of Function and Survival (CAFS).

The researchers reported the following findings:

  • The interim analysis showed that the observed mean change from baseline in ALSFRS-R at week 50 was −14.67 points for ravulizumab and −13.33 points for placebo, with no significant difference between the groups.
  • Based on these data, the trial was terminated for futility.
  • The primary analysis at week 50 showed no significant difference in CAFS between groups.
  • Overall incidence rates for treatment-emergent adverse events were similar for ravulizumab (80.0% participants and placebo 85.0% participants).

"The outcomes of this RCT indicate that an unmet need remains regarding the treatment of patients with ALS, as current disease management is mainly supportive and palliative," the researchers wrote.

"There is a critical need for highly effective, novel treatments to slow functional decline and extend survival in patients with ALS," they concluded.

Reference:

Genge A, van den Berg LH, Frick G, et al. Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. Published online September 11, 2023. doi:10.1001/jamaneurol.2023.2851


JAMA Neurologyravulizumabamyotrophic lateral sclerosiscomplement C5 inhibitorALS
Source : JAMA Neurology
Medha Baranwal
Medha Baranwal

    MSc. Biotechnology

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    Prediabetes and the Mind: Unraveling Cognitive and Mental Health Risks

    Prediabetes and the Mind: Unraveling Cognitive and Mental Health Risks

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    Aspirin in Primary Prevention- When to Consider?

    Aspirin in Primary Prevention- When to Consider?

    View All

    Journal Club Today

    Journal Club: To assess knowledge, attitude, and practices of housekeeping and sanitation workers for infection control in clinical service laboratories of a tertiary care hospital

    Journal Club: To assess knowledge, attitude, and practices of housekeeping and sanitation workers...

    View All

    Health News Today

    Health Bulletin 21/ May/ 2025

    Health Bulletin 21/ May/ 2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok